 | |
| Clinical data | |
|---|---|
| Trade names | Elamol, Tofacine, Tofalin |
| Other names | tofenacin hydrochloride ( USAN US) |
|
Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.035.746 |
| Chemical and physical data | |
| Formula | C17H21NO |
| Molar mass | 255.361 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma). [1] [2] [3] It acts as a serotonin-norepinephrine reuptake inhibitor, [4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients. [5] [6]
See also
References
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041. ISBN 978-3-88763-075-1. Retrieved 19 May 2012.
- ^ Buckingham J (1996). Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074. ISBN 978-0-412-54090-5. Retrieved 19 May 2012.
- ^ Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. 2013-01-15. p. 3268. ISBN 978-0-8155-1526-5. Retrieved 19 May 2012.
- ^ van Dijk J, Hartog J, Hillen FC (1 January 1978). "Non-Tricyclic Antidepressants". In Ellis GP, West GB (eds.). Progress in Medicinal Chemistry. Elsevier. p. 284. ISBN 978-0-7204-0655-9. Retrieved 19 May 2012.
- ^ Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research. 4 (6): 435–440. doi: 10.1177/030006057600400610. PMID 800383. S2CID 40083513.
- ^ Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry. 22 (6): 246–249. doi: 10.1055/s-2007-1014608. PMID 2616635. S2CID 39693625.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Trade names | Elamol, Tofacine, Tofalin |
| Other names | tofenacin hydrochloride ( USAN US) |
|
Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.035.746 |
| Chemical and physical data | |
| Formula | C17H21NO |
| Molar mass | 255.361 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma). [1] [2] [3] It acts as a serotonin-norepinephrine reuptake inhibitor, [4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients. [5] [6]
See also
References
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041. ISBN 978-3-88763-075-1. Retrieved 19 May 2012.
- ^ Buckingham J (1996). Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074. ISBN 978-0-412-54090-5. Retrieved 19 May 2012.
- ^ Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. 2013-01-15. p. 3268. ISBN 978-0-8155-1526-5. Retrieved 19 May 2012.
- ^ van Dijk J, Hartog J, Hillen FC (1 January 1978). "Non-Tricyclic Antidepressants". In Ellis GP, West GB (eds.). Progress in Medicinal Chemistry. Elsevier. p. 284. ISBN 978-0-7204-0655-9. Retrieved 19 May 2012.
- ^ Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research. 4 (6): 435–440. doi: 10.1177/030006057600400610. PMID 800383. S2CID 40083513.
- ^ Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry. 22 (6): 246–249. doi: 10.1055/s-2007-1014608. PMID 2616635. S2CID 39693625.
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |